Get started
Direxion Daily S&P Biotech Bull 3X SharesDirexion Daily S&P Biotech Bull 3X SharesDirexion Daily S&P Biotech Bull 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

No trades
See on Supercharts
Overview Chart Analysis Holdings News
Ideas
Discussions Seasonals

LABU trade ideas

watch this ETF, target 48Emergency: U.S. declares monkeypox a public health emergency The Direxion Daily S&P Biotech Bull 3X Shares fund provides exposure to a large range of high-performing biotechnology companies in the US. Managed by Direxion, which is headquartered in Milwaukee, Wisconsin this fund was established in May 2015. The key objective of the Direxion Daily S&P Biotech Bull 3X Shares ETF is to provide 300% of the daily investment performance of the S&P Biotechnology Select Industry Index, but this fund should not be expected to provide these results for periods greater than a single day. All the companies held by this fund are part of the S&P 500, which includes large companies listed on stock exchanges within the United States. The fund generally invests the majority of its assets in stocks for companies that are listed in the index. The base currency for this fund is USD. Stock for the Direxion Daily S&P Biotech Bull 3X Shares ETF is listed on the NYSE under the ticker LABU.US. This fund only includes investments in the biotechnology industry. This fund is non-diversified. As of 10 December 2021, some of the fund's top holdings include Acceleron Phar/D, Cytokinetics, Sarepta Therapeutics Inc De, Seagen Inc., Tg Therapeutics, Seres Therapeutics, Chemocentryx, Dynavax Technologies, Iovance Biotherapeutics Inc., and Ironwood Pharma Class A.
AMEX:LABULong
by xyxfreeman
1
LABU, my all in bet with a stop, of course.I honestly cannot find a better opportunity in the market than LABU currently. The ETF is XBI*3, which has demonstrated some major cyclicality and is currently selling below it's 2015 highs. My analysis is as follows: Record volumes on LABU specifically, but more or less XBI too. This implies we've hit a level of importance. It's quite clearly been consolidating for the past week; a sign that if we've bottomed out and that the strongest selling is in the past. It's normal for LABU to experience pull backs lasting, about 1 month, 3 months or whatever. We are currently 360 days into a -50% pullback on XBI and 30 days into another significant pullback now. The most recent leg down was clearly in relation to the entire market selloff, XBI was one of the sectors that was hardest hit during the price action. My view is as follows, I used the same logic during covid when I split my account between OVV and CCR: If conditions return to that of December, which were markedly poor, LABU will probably sell for 40, if conditions returned to October, 60 is entirely possible. Both possibilities are quite clearly in the cards for this year, and it looks like the market has already begun to turn around. My personal bias is that this sector is probably undervalued, because the firms that represent it are almost certainly worth more than what they sold for in 2015 (although I havent done any work on any of them) and my sub-grade technical analysis suggest that we've possibly hit a bottom, and you can find a great risk to reward trade by owning this security. At this time, with the price at 17.5~ I am 100% in LABU but I have the stop at 16.5. So my expected risk to reward is 10-1, which is unheard of. TL:DR XBI has fallen a lot. Its been down for a while. Volumes have hit a record in it's parent ETF, XBI If conditions return to December, I'll make 100%. If I'm wrong, I'll lose 7~%. Naturally, I have a strong conviction in the possibilities with this type of trade. I would strongly advise that you don't follow it. Despite the underlying being an ETF, it's clearly a high-risk high-reward type of deal.
AMEX:LABULong
by JamesMBee
22
LABU Bullish. LABUAs expected SNP Biotech sector is in the green and this has been reflected in our last update with every new and emerging biotech stock that we reviewed being convincingly bullish. We have and end to a zig zag formation here, this a corrective X Wave or a start of a new impulse ensures. We shall see which shall transpire in this instance. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
AMEX:LABULong
by Rykin_Capital